Harrow Health, Inc. (HROW)
| Market Cap | 227.54M |
| Revenue (ttm) | 52.50M |
| Net Income (ttm) | 9.77M |
| Shares Out | 26.58M |
| EPS (ttm) | 0.37 |
| PE Ratio | 22.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $8.56 |
| Previous Close | $8.94 |
| Change ($) | -0.38 |
| Change (%) | -4.25% |
| Day's Open | 8.93 |
| Day's Range | 8.53 - 9.11 |
| Day's Volume | 126,318 |
| 52-Week Range | 4.65 - 11.24 |
Harrow Health (NASDAQ:HROW) posted a 7.77% decrease in earnings from Q4. Sales, however, increased by 5.81% over the previous quarter to $15.44 million.
NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its new...
Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease Multi-center Retrospective Study Demonstrates Statistically Significant Reducti...
Shares of Harrow Health (NASDAQ:HROW) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 102.00% year over year to $0.01, which beat ...
Highlights for First Quarter 2021:
NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that the Company has c...
NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of an addi...
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., April 27, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the firs...
NASHVILLE, Tenn., April 20, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its u...
NASHVILLE, Tenn., April 15, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its u...
NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced it has commenced an underwritten registered public offe...
NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced certain preliminary unaudited financial results for the...
Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Company's Prior-Quarter Momentum Continues in Fourth Quarter Company's Prior-Quarter Momentum Continues in Fourth Quarter
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourt...
Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021
The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.
Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the American Associ...
NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow's Chief Executive Officer, and Andrew Boll, Harrow's Chief Financial Officer...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health's Letter to S tockhold...
Harrow Health (NASDAQ: HROW) will be releasing its next round of earnings this Monday, November 09. For all of the relevant information, here is your guide for Monday's Q3 earnings announcement.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 fin...
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors.
As of late, it has definitely been a great time to be an investor Harrow Health.
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
On Monday, August 10, Harrow Health (NASDAQ: HROW) will release its latest earnings report.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 f...
The study published in Clinical Ophthalmology shows equivalent clinical outcomes to separately dosed eyedrops and a strong patient preference for the ImprimisRx proprietary combination drop therapy for ...
NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index...
Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Healt...
Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2020 Results - Earnings Call Transcript
Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning telemedicine services ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning tele...
NASHVILLE, Tenn., March 17, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors.
Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health, Inc. (HROW) CEO Mark Baum on Q4 2019 Results - Earnings Call Transcript
Agreement expands locations served and access to new ImprimisRx formulations Agreement expands locations served and access to new ImprimisRx formulations
ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery
ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed du...
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the devel... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1998 |
| Stock Exchange NASDAQ | Ticker Symbol HROW |
Analyst Forecasts
According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 75.23% from the latest price.